MedTrace Logo

Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

NCT02833467 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2019-08-28

No results posted yet for this study

Summary

Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations. This study is to evaluate the feasibility and application value by using NGS into identifying genomic mutations in multiple or multifocal primary lung cancers in cell-tumor DNA (ctDNA) from surgical patients

Conditions

  • Carcinoma
  • Non-small-cell Lung Cancer
  • Thoracic Neoplasms

Sponsors & Collaborators

  • San Valley Biotechnology Incorporated

    collaborator UNKNOWN

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Kezhong Chen, M.D. · Peking University People's Hospital

  • Jun Wang, M.D. · Peking University People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-01-31
Completion
2021-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02833467 on ClinicalTrials.gov